Patient-tailored therapy in rheumatoid arthritis: an editorial review
Authors:
- Hans U SchererHSHans U Scherer
- Thomas DörnerTDThomas Dörner
- Gerd R BurmesterGBGerd R Burmester
- 1 May 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 22 (3) , 237-245
Abstract
The list of therapeutic targets for the treatment of rheumatic diseases constantly grows. As a consequence, a growing number of agents that are specifically directed against these targets become clinically available. However, the more diverse (and expensive) the armamentarium, the more its use should be guided by informed decisions for an optimal treatment. Such personalized, patient-tailored therapy is still not a reality in rheumatology practice. However, several important steps have recently been made towards achievement of this important goal. On the basis of the multifactorial nature of the pathogenesis of rheumatic diseases, the quest for single biomarkers that predict treatment response has proven difficult. Instead, biomarker signatures derived from genetic and proteomic expression studies using various biomaterials are being identified and demonstrate predictive value. Research focus has so far been placed on treatment responses to methotrexate and tumor necrosis factor antagonists, but interesting findings are already available for other agents as well. Although still in their infancy in rheumatology, personalized treatment approaches offer the potential for improved safety and efficacy for the patient and ultimately have promises to reduce societal costs.Keywords
This publication has 81 references indexed in Scilit:
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- Association of a single‐nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritisArthritis & Rheumatism, 2009
- When the levee doesn't break: A novel role of β2‐glycoprotein I to protect against congenital heart blockArthritis & Rheumatism, 2009
- Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritisClinical and Experimental Immunology, 2008
- Rheumatoid arthritis association at 6q23Nature Genetics, 2007
- Two independent alleles at 6q23 associated with risk of rheumatoid arthritisNature Genetics, 2007
- The performance of anti–cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis RegisterArthritis & Rheumatism, 2007
- A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent‐onset rheumatoid arthritisArthritis & Rheumatism, 2007
- Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2007
- Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritisRheumatology, 2004